Executive Summary
The comprehensive list of Anti-CD152 Antibody that are marketed for different indications and the products that are in development. The main objective of this report is to provide a comprehensive secondary research and market analysis of Anti-CD152 Antibody pipeline products that are in Phase 3, Phase 2, Phase 1, preclinical and discovery across different indications. This report also provides comprehensive research on the companies that are working on Anti-CD152 Antibody including the deals and acquisitions.
Report Coverage:
Clinical (Phase Products)
Non-clinical (Preclinical and Discovery)
Dormant and Discontinued
Companies Mentioned
ImmunOs Therapeutics AG, Bioinvent International, Tikcro Technologies, Nativis, Agenus, MacroGenics, Ultimovacs AS
Request Sample Report @ https://www.wiseguyreports.com/sample-request/3271727-anti-cd152-antibody-pipeline-analysis-2018
Table of Content:
Executive Summary
Overview of Anti-CD152 antibodies
Recent Trends
Pipeline Therapeutics
Therapeutics under Development by Companies
Late State Products
· Product Description
· Research and Development
· Product Development Activities
Mid Stage Products
· Product Description
· Research and Development
· Product Development Activities
Early Stage Products
· Product Description
· Research and Development
· Product Development Activities
Therapeutic Assessment
· Assessment by Route of Administration
· Assessment by Phase & Route of Administration
· Assessment by Molecule Type
· Assessment by Phase & Molecule type
Collaborations and Acquisitions Details
Dormant Products
Discontinued Products
Appendix
Methodology
About Adroit healthcare services
Disclaimer
Table 1: Products Under Development for anti-CD152 antibodies, 2018
Table 2: Products under Development by Companies, 2018
Table 3: Late Stage Products, 2018
Table 4: Mid Stage Products, 2018
Table 5: Early Stage Products, 2018
Table 6: Pre-Clinical and Discovery Products, 2018
Table 7: Assessment by Route of Administration, 2018
Table 8: Assessment by Stage and Route of Administration, 2018
Table 9: Assessment by Molecule Type, 2018
Table 10: Assessment by Stage and Molecule Type, 2018
Table 11: Comparative Analysis
Table 12: Dormant Products
Table 13: Discontinued Products
Figure 1: Products Under Development for anti-CD152 antibodies, 2018
Figure 2: Products under Development by Companies, 2018
Figure 3: Late Stage Products, 2018
Figure 4: Mid Stage Products, 2018
Figure 5: Early Stage Products, 2018
Figure 6: Pre-Clinical and Discovery Products, 2018
Figure 7: Assessment by Route of Administration, 2018
Figure 8: Assessment by Stage and Route of Administration, 2018
Figure 9: Assessment by Molecule Type, 2018
Figure 10: Assessment by Stage and Molecule Type, 2018
Figure 11: Comparative Analysis
Figure 12: Dormant Products
Figure 13: Discontinued Products
Continuous…
For further information on this report, visit – https://www.wiseguyreports.com/reports/3271727-anti-cd152-antibody-pipeline-analysis-2018
Media Contact
Company Name: Wiseguyreports.com
Contact Person: Norah Trent
Email: Send Email
Phone: +1 646 845 9349, +44 208 133 9349
City: Pune
State: Maharashtra
Country: India
Website: www.wiseguyreports.com